MX2015012896A - Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa. - Google Patents

Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa.

Info

Publication number
MX2015012896A
MX2015012896A MX2015012896A MX2015012896A MX2015012896A MX 2015012896 A MX2015012896 A MX 2015012896A MX 2015012896 A MX2015012896 A MX 2015012896A MX 2015012896 A MX2015012896 A MX 2015012896A MX 2015012896 A MX2015012896 A MX 2015012896A
Authority
MX
Mexico
Prior art keywords
pyrrolo
pyridine
kinase inhibitors
cdk9 kinase
compounds
Prior art date
Application number
MX2015012896A
Other languages
English (en)
Inventor
Yunsong Tong
Zhi-Fu Tao
Thomas Penning
Andrew J Souers
Jianchun Gong
Guidong Zhu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Priority claimed from PCT/US2014/025740 external-priority patent/WO2014151444A1/en
Publication of MX2015012896A publication Critical patent/MX2015012896A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se describen compuestos de la Fórmula (lIIa), (ver Fórmula) en donde R1, R2, R3, X1, X2, X3, X4, X5, tienen los valores definidos anteriormente en la especificación, y sales farmacéuticamente aceptables de los mismos. Los compuestos pueden usarse como agentes en el tratamiento de enfermedades, incluyendo el cáncer. También se proporcionan composiciones farmacéuticas que comprende uno o más compuestos de la Fórmula (lIIa).
MX2015012896A 2013-03-14 2014-03-13 Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa. MX2015012896A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN745DE2013 2013-03-14
US201361904842P 2013-11-15 2013-11-15
PCT/US2014/025740 WO2014151444A1 (en) 2013-03-14 2014-03-13 Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2015012896A true MX2015012896A (es) 2016-06-02

Family

ID=54249678

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012899A MX2015012899A (es) 2013-03-14 2014-03-13 Pirrolo [2,3-b] piridina como inhibidores de quinasa cdk9.
MX2015012896A MX2015012896A (es) 2013-03-14 2014-03-13 Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015012899A MX2015012899A (es) 2013-03-14 2014-03-13 Pirrolo [2,3-b] piridina como inhibidores de quinasa cdk9.

Country Status (9)

Country Link
US (1) US9796708B2 (es)
EP (2) EP2970264A1 (es)
JP (2) JP2016514113A (es)
CN (2) CN105246890A (es)
AR (1) AR101528A1 (es)
AU (2) AU2014234077A1 (es)
BR (2) BR112015023187A2 (es)
CA (2) CA2905935A1 (es)
MX (2) MX2015012899A (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843872B (zh) * 2017-09-20 2022-08-30 杭州英创医药科技有限公司 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
CN111328333B (zh) * 2019-09-29 2023-10-03 烟台迈百瑞国际生物医药股份有限公司 一种酸法制备抗体药物偶联物中间体的方法及其应用
JP2023501081A (ja) * 2019-10-18 2023-01-18 リード ファーマ ホールディング ビー．ブイ． エストロゲン関連受容体アルファ（ＥＲＲα）モジュレーター
WO2022078309A1 (zh) * 2020-10-12 2022-04-21 上海海雁医药科技有限公司 取代的二(吡啶-2-基)胺衍生物、其组合物及医药上的用途
CN116685588A (zh) * 2020-12-25 2023-09-01 南京明德新药研发有限公司 吡啶并吡咯类化合物的晶型、制备方法及其应用
CN112852874B (zh) * 2021-02-04 2023-05-23 中国农业科学院兰州兽医研究所 Hdac5基因敲除的bhk-21细胞系及其构建方法和应用
CN113248496B (zh) * 2021-05-06 2022-02-11 东南大学 吡咯并吡啶类化合物及其盐及其用途
CN113666934B (zh) * 2021-07-28 2023-06-23 北京深度制耀科技有限公司 Cdk9激酶抑制剂

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
DE69631347T2 (de) 1995-09-15 2004-10-07 Upjohn Co Aminoaryl oxazolidinone n-oxide
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
GB9930698D0 (en) * 1999-12-24 2000-02-16 Rhone Poulenc Rorer Ltd Chemical compounds
EE05180B1 (et) 1999-12-24 2009-06-15 Aventis Pharma Limited Asaindooli sisaldav farmatseutiline kompositsioon raviotstarbeliseks kasutamiseks, asaindoolid ning nende kasutamine ravimite valmistamiseks, mis on ette n„htud proteiinikinaasi kataltilise toime p„rssimiseks
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
ES2294494T3 (es) 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
PL1768967T3 (pl) 2004-07-20 2009-09-30 Symed Labs Ltd Nowe związki pośrednie do wytwarzania linezolidu oraz związki pokrewne
AR050365A1 (es) 2004-08-02 2006-10-18 Osi Pharm Inc Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos.
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
WO2007076348A2 (en) 2005-12-23 2007-07-05 Smithkline Beecham Corporation Azaindole inhibitors of aurora kinases
PE20080925A1 (es) * 2006-09-22 2008-09-04 Glaxo Group Ltd DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA)
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US20080188524A1 (en) 2006-10-25 2008-08-07 Martin Augustin Methods of treating pain
CN101568530A (zh) * 2006-12-22 2009-10-28 诺瓦提斯公司 吲哚-4-基-嘧啶-2-基胺衍生物及其作为细胞周期蛋白依赖性激酶抑制剂的用途
WO2008098857A1 (en) 2007-02-15 2008-08-21 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
EP2139869A2 (en) 2007-04-13 2010-01-06 SuperGen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
KR20100012031A (ko) 2007-04-19 2010-02-04 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
GB0710528D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
EP2209774A1 (en) 2007-10-02 2010-07-28 Concert Pharmaceuticals Inc. Pyrimidinedione derivatives
CA2702008A1 (en) 2007-10-12 2009-04-16 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
US20090118276A1 (en) * 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
GB0804592D0 (en) * 2008-03-12 2008-04-16 Glaxo Group Ltd Novel compounds
CN102143746A (zh) * 2008-07-03 2011-08-03 埃克塞利希斯股份有限公司 Cdk 调节剂
NZ591176A (en) 2008-08-22 2012-11-30 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
IN2012CH01573A (es) * 2012-04-20 2015-07-10 Advinus Therapeutics Ltd
WO2013157021A1 (en) * 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof

Also Published As

Publication number Publication date
CN105324380A (zh) 2016-02-10
CA2905530A1 (en) 2014-09-18
AU2014234077A1 (en) 2015-10-01
AU2014231567A1 (en) 2015-10-01
JP2016514113A (ja) 2016-05-19
MX2015012899A (es) 2016-06-02
BR112015023187A2 (pt) 2017-07-18
US20160060257A1 (en) 2016-03-03
US9796708B2 (en) 2017-10-24
CN105246890A (zh) 2016-01-13
EP2970264A1 (en) 2016-01-20
EP2970278A1 (en) 2016-01-20
CA2905935A1 (en) 2014-09-25
JP2016516713A (ja) 2016-06-09
BR112015023356A2 (pt) 2017-07-18
EP2970278A4 (en) 2016-12-07
AR101528A1 (es) 2016-12-28

Similar Documents

Publication Publication Date Title
PH12016500024A1 (en) Bromodomain inhibitor
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
PH12019500776A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12015502004A1 (en) Tetracyclic bromodomain inhibitors
PH12018500121A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
MX2015012431A (es) Pirrol amida como inhibidores.
MX2015012896A (es) Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa.
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
MX2015012005A (es) Inhibidores de bromodominio.
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
MX2016007346A (es) Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio.
MX2015012158A (es) Inhibidores de bomodominio tetraciclicos fusionados.
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
TN2016000458A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer.
EA027213B9 (ru) Соединения пиразолопиримидина в качестве ингибиторов киназ
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
PH12015502159A1 (en) Chemical entities
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX2016007440A (es) Inhibidores del bromodominio.
TW201613864A (en) Novel compounds
GB201209587D0 (en) Therapeutic compounds
MX2018008362A (es) Derivados de quinolin-2-ona.
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.